Amber Salzman | Chief Executive Officer
Epicrispr Biotechnologies

Amber Salzman is an experienced biotech CEO and board director with 25+ years at GlaxoSmithKline and leadership of multiple biotech companies. She is a visionary leader and accomplished executive. With over two decades of experience in drug development and commercialization, she has a proven track record of driving innovation and delivering results. As the Chief Executive Officer of Epicrispr Biotechnologies, Amber is at the forefront of advancing cutting-edge therapies that have the potential to revolutionize healthcare.

Amber's career has been defined by her passion for translating scientific breakthroughs into tangible treatments that improve patient outcomes. She has a deep understanding of the regulatory landscape and a keen ability to navigate complex challenges in the biotech sector. Under her leadership, Epicrispr Biotechnologies has emerged as a key player in the field of advanced therapies, with a focus on epigenetic editing technologies and an Facioscapulohumeral Muscular Dystrophy (FSHD) program in the clinic. She is committed to driving innovation, fostering collaboration, and ultimately, bringing life-changing treatments to patients in need.